Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Ethyol amifostine chemoprotective agent: Phase II data; marketed

UBS reported that an infusion of 300 mg/m2 Ethyol given daily prior to treatment with carboplatin and radiation therapy reduced the incidence of mucositis

Read the full 246 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE